Anti-Ebola Nucleoprotein [KZ51]

Description:

Recombinant monoclonal antibody to Ebola Nucleoprotein. Manufactured using AbAb’s Recombinant Platform with variable regions (i.e. specificity) from the phage display antibody KZ51.

Clone Name:

KZ51

Published Application(s):

IP, WB, ELISA, IF

Published Species Reactivity:

Ebola Virus (Zaire, Ivory Coast, Reston, Sudan)

Products based on this clone:

{{heading}}

Please Select

Ab00692-1.1 Anti-Ebola Nucleoprotein [KZ51]
Ebola Virus (Zaire, Ivory Coast, Reston, Sudan)
Mouse IgG1
Purified
Ships in 4-5 weeks

Ab00692-23.0 Anti-Ebola Nucleoprotein [KZ51]
Ebola Virus (Zaire, Ivory Coast, Reston, Sudan)
Rabbit IgG
Purified
In Stock

Ab00692-10.0 Anti-Ebola Nucleoprotein [KZ51]
Ebola Virus (Zaire, Ivory Coast, Reston, Sudan)
Human IgG1
Purified
In Stock

Alternative Name(s) of Target: NP; Ebola NP; EBOV NP
Immunogen: This antibody was derived from a human survivor of the 1995 Kikwit outbreak of Ebola.

Specificity: This antibody binds to the nucleoprotein of four Ebola virus strains and has a specificity found in convalescent patients. No cross-reactivity with other proteins (e.g. GP) was detected by radioimmunoprecipitation.

Application Notes: This antibody is broadly cross-reacting between different Ebola strains and competes with antibodies naturally occuring in covalescent patients. By IF, this antibody has higher reactivity towards fixed virus than to live virus - though both may be detected. It has also been used as a positive control in the development of anti-Ebola polyclonal goat antibodies (Boisen et al. 2015).

Antibody first published in: Maruyama et al. Ebola virus can be effectively neutralized by antibody produced in natural human infection. J Virol. 1999 Jul; 73(7): 6024–6030. PMID:10364354
Note on publication: Describes the generation and functional characterization of this antibody.